Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

March 23, 2016

Primary Completion Date

June 11, 2019

Study Completion Date

August 19, 2019

Conditions
Venous ThromboembolismCancer
Interventions
DRUG

Rivaroxaban

Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months

DRUG

low-molecular heparine

"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily"

Trial Locations (1)

52074

Uniklinik, Aachen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Charite University, Berlin, Germany

OTHER

collaborator

Bayer

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER